Media about us

• Producers criticize excessive pharma market regulation in Russia

  28 September 2021 The Pharma Letter

  

  Excessive regulation of the Russian pharmaceutical market and the lack of drug insurance system is leading to a shortage of some vital and effective drugs in the local market, according to recent statements by representatives of producers and analysts. 

• New Russian proctology medicine makes inroads in EU markets

  26 July 2021 Marchmont Innovation News

  

  NovaMedica, a Russian pharmaceutical company and portfolio project of the national nanotech company Rusnano, has developed what might emerge into a market-winning new drug for colorectal therapy.

• Bayer found a pill

  31 May 2021 ScoopTrade

  

  Concern Bayer will expand its portfolio of drugs for the treatment of hemorrhoids with the development of the Russian “NovaMedica” based on nifedipine and lidocaine. The German company already holds about 40% of the market for such funds. Pharmaceutical market experts call the deal one of the rare ones: foreign companies do not often acquire rights to Russian medicines.

• NovaMediсa and Unipharm to Build Production Unit in Russia

  29 July 2019 GMP News

  

  Major Russian pharmaceutical company NovaMedica and the US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen^®, a hormone secreted by the pineal gland in a 24-hour circadian rhythm, regulating the normal sleep/wake cycle. Production capacity expected to reach hundreds of thousands of packages per year. It will be enough to meet the requirements of patients living in the territory of the EAEU.

• A pill is changing citizenship

  23 July 2019 RBG - Russian Business Guide

  

  The Russian pharmaceutical market is considered to be one of the most dynamic ones. In recent years, the annual growth is about 10%. The state policy that stimulates the production localization is effectively implemented. A new investment instrument has been launched in Russia – a special investment contract (SPIC). On March 7, 2018, NovaMediсa, a portfolio company of RUSNANO, concluded the largest in the pharmaceutical industry a special investment contract (SPIC) with the Russian Federation represented by the Ministry of Industry and Trade of Russia and the Kaluga Region to establish the production of sterile injectable dosage forms. 

• NovaMedica, Pharmsynthez to create integrated drug production

  19 June 2019 AKM News

  

  Russian drug companies NovaMedica and Pharmsynthez have launched a joint project to make a number of effective drugs available to Russian patients within 1.5-2 years. Integrated local production of these drugs will be set up in Russia, RUSNANO informed.

• Para la transferencia de tecnologías... ¡Estate preparado!

  18 April 2019 GMP News

  

  Si quiere atraer a un socio internacional (proveedor) para localizar en su empresa sus productos, debe seguir con exactitudm las normas internacionales. Conocer y ser capaz de realizar transferencia correctamente. Al parecer, no hay de que discutir. Pero aun, prevalecen los antiguos enfoques en la organization de transferencia de tecnologias farmaceuticas: "Escribannos los componentes, y nosotros lo dominaremos todo aqui por nuestra cuenta".

• Bilfinger soll Pharmaanlage für Novamedica liefern

  11 February 2019 Chemic Technic

  

  Der Mannheimer Industriedienstleister Bilfinger hat vom russischen Pharmaunternehmen Novamedica den Auftrag zur Lieferung einer Arzneimittel-Produktionsanlage erhalten. Das Projekt soll von Bilfinger Industrietechnik Salzburg abgewickelt werden und umfasst die Konstruktion und Errichtung von drei Ansatzsystemen zur Herstellung steriler Arzneiformen. Es ist der erste Auftrag für das Bilfinger-Tochterunternehmen Russland. 

• Import Substitution and Innovations of Kaluga Pharmaceutical Cluster. Results of 2018

  22 January 2019 CIS GMP News, 3 (4) / Winter 2019

  

  For seven years past from its existence Kaluga Pharmaceutical Cluster has been dynamically developing significantly exceeding the growth rates in other economic sectors of the region. And the question is not only about opening of manufacturing facilities but also about further localization and extension of manufacturing capacity of already existing plants of both Russian and foreign manufacturers. 2018 was no exception. In March of 2018, NovaMedica LLC concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga Region. 

• New Chlamydia Test Delivers Results in About 30 Minutes

  11 December 2018 National Institutes of Health

  

  NIBIB-funded researchers recently validated a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby stemming the further spread of disease. Other analyses showed most women preferred the easy self-collection method the test offers.